Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The enhancement of central serotonin system function underlies the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs), which have become the most commonly used class of antidepressant agents. However, many individuals experience depressive episodes that are resistant to SSRI treatment. Homeostatic mechanisms that limit the extent to which SSRIs enhance serotonergic neurotransmission have been implicated in this phenomenon. Here, we report a novel strategy for enhancing the efficacy of SSRIs. Using in vivo microdialysis methods in rats, the nonselective 5-HT2 receptor antagonist ketanserin was observed to produce a robust augmentation of citalopram-, fluoxetine-, and sertraline-induced elevations of hippocampal extracellular serotonin levels. Similar effects were also observed in cortex. The potentiation of SSRI-induced increases in hippocampal serotonin levels was reproduced by the 5-HT(2C) receptor-selective antagonists SB 242084 and RS 102221, but not by the 5-HT(2A) receptor-selective antagonist MDL 100 907. Although 5-HT(2C) receptor antagonists augmented the actions of SSRIs, they had no effect on extracellular serotonin levels or tail suspension responses when administered alone. These results were in strong accord with independent findings using a line of 5-HT(2C) receptor-null mutant mice. Although this mutation did not affect baseline extracellular serotonin levels or tail suspension test (TST) behavior, it enhanced fluoxetine effects on serotonin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, studies have shown that antagonism of 5-HT 2A/2C receptors can enhance the effects of SSRIs such as fluoxetine. 360 , 361”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [360]
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., & Julius, D. (1995) · Nature · doi:10.1038/374542a0 · Cited by 1,274
Self-citationDepression: Perspectives from Affective Neuroscience
Davidson, R. J., Pizzagalli, D., Nitschke, J. B., & Putnam, K. (2002) · Annual Review of Psychology · doi:10.1146/annurev.psych.53.100901.135148 · Cited by 1,138
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain
Wright, D. E., Seroogy, K. B., Lundgren, K. H., Davis, B. M., & Jennes, L. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903510304 · Cited by 549
Gurevich, I., Tamir, H., Arango, V., Dwork, A. J., Mann, J. J., & Schmauss, C. (2002) · Neuron · doi:10.1016/s0896-6273(02)00660-8 · Cited by 377
Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS
Clemett, D. A., Punhani, T., S. Duxon, M., Blackburn, T. P., & Fone, K. C. F. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00086-6 · Cited by 373
Cited by
Cryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“360,361 Third, long-term use of SSRIs can increase 5-HT transmission in the LC, 362 thereby increasing the release of GABA to exert inhibitory effects on NA neurons.”
BackgroundBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Self-citationMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
Dopamine, depression and antidepressants
Dailly, E., Chenu, F., Renard, C. E., & Bourin, M. (2004) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00287.x · Cited by 302
Serotonin activates the hypothalamic–Pituitary–Adrenal axis via serotonin 2C receptor stimulation
Heisler, L. K., Pronchuk, N., Nonogaki, K., Zhou, L., Raber, J., Tung, L., Yeo, G. S. H., O'Rahilly, S., Colmers, W. F., Elmquist, J. K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2584-06.2007 · Cited by 292
Self-citationMillan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 283
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Homberg, J. R., Olivier, J. D. A., Smits, B. M. G., Mul, J. D., Mudde, J., Verheul, M., Nieuwenhuizen, O. F. M., Cools, A. R., Ronken, E., Cremers, T., et al. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.03.030 · Cited by 259
Self-citationOlivier, J. D. A., Van Der Hart, M. G. C., Van Swelm, R. P. L., Dederen, P. J., Homberg, J. R., Cremers, T., Deen, P. M. T., Cuppen, E., Cools, A. R., & Ellenbroek, B. A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.12.032 · Cited by 246
Self-citationInnovative approaches for the development of antidepressant drugs: Current and future strategies
Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.590 · Cited by 228
Fletcher, P. J., Tampakeras, M., Sinyard, J., & Higgins, G. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0891-z · Cited by 211
Vanover, K. E., Weiner, D. M., Makhay, M., Veinbergs, I., Gardell, L. R., Lameh, J., Del Tredici, A. L., Piu, F., Schiffer, H. H., Ott, T. R., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097006 · Cited by 204
Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control
Sharp, T., Boothman, L., Raley, J., & Quérée, P. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.009 · Cited by 190
Burghardt, N. S., Bush, D. E. A., McEwen, B. S., & LeDoux, J. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.023 · Cited by 179
Differentiating antidepressants of the future: Efficacy and safety
Rosenzweig-Lipson, S., Beyer, C. E., Hughes, Z. A., Khawaja, X., Rajarao, S. J., Malberg, J. E., Rahman, Z., Ring, R. H., & Schechter, L. E. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.002 · Cited by 179
Serotonin receptors in depression and anxiety: Insights from animal studies
Żmudzka, E., Sałaciak, K., Sapa, J., & Pytka, K. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.050 · Cited by 173
Phytochemistry and pharmacology of anti-depressant medicinal plants: A review
Martins, J., & Brijesh, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.044 · Cited by 167
Dremencov, E., El Mansari, M., & Blier, P. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0930 · Cited by 127
De Deurwaerdère, P., & Di Giovanni, G. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 163
Treatment-resistant depression: are animal models of depression fit for purpose?
Willner, P., & Belzung, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4034-7 · Cited by 164
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6Receptor Stimulation
Svenningsson, P., Tzavara, E. T., Qi, H., Carruthers, R., Witkin, J. M., Nomikos, G. G., & Greengard, P. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3110-06.2007 · Cited by 160
Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls
Paterson, L. M., Tyacke, R. J., Nutt, D. J., & Knudsen, G. M. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.104 · Cited by 145
Serotonin–dopamine interaction: electrophysiological evidence
DIGIOVANNI, G., DIMATTEO, V, PIERUCCI, M., & ESPOSITO, E. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00903-5 · Cited by 151
Strategies for producing faster acting antidepressants
Adell, A., Castro, E., Celada, P., Bortolozzi, A., Pazos, Á., & Artigas, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03398-2 · Cited by 146
Sánchez, C. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_295.x · Cited by 128
5-HT2C receptors in psychiatric disorders: A review
Chagraoui, A., Thibaut, F., Skiba, M., Thuillez, C., & Bourin, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.006 · Cited by 133
Kara, N., Stukalin, Y., & Einat, H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.003 · Cited by 133
In vivo evidence that 5‐HT2C receptors inhibit 5‐HT neuronal activity via a GABAergic mechanism
Boothman, L. J., Raley, J., Denk, F., Hirani, E., & Sharp, T. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706935 · Cited by 133
New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders
Giovanni, G. D., & Deurwaerdère, P. D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.009 · Cited by 130
5-HT Receptors and the Development of New Antidepressants
Ślifirski, G., Król, M., & Turło, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169015 · Cited by 126
Dremencov, E., Newman, M. E., Kinor, N., Blatman‐Jan, G., Schindler, C. J., Overstreet, D. H., & Yadid, G. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.09.013 · Cited by 118
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
Rosenzweig-Lipson, S. J., Sabb, A. L., Stack, G., Mitchell, P., Lucki, I., Malberg, J. E., Grauer, S. M., Brennan, J. A., Cryan, J. F., Rizzo, S. J. S., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0710-6 · Cited by 115
Amargós-Bosch, M., López-Gil, X., Artigas, F., & Adell, A. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005900 · Cited by 104
Dhonnchadha, B. Á. N., Fox, R. G., Stutz, S. J., Rice, K. C., & Cunningham, K. A. (2009) · Behavioral Neuroscience · doi:10.1037/a0014592 · Cited by 114
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
“Black et al. (2000) identified 53 different symptoms within the condition (with dizziness being the most common) and proposed a diagnostic criteria for SSRI discontinuation syndrome that requires two or more of the described symptoms developing within 1–7 days of discontinuation (or reduction in…”
BackgroundDremencov, E., Mansari, M. E., & Blier, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.015 · Cited by 106
Developments in the field of antidepressants, where do we go now?
Artigas, F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.04.013 · Cited by 103
Lack of CB1 receptor activity impairs serotonergic negative feedback
Aso, E., Renoir, T., Mengod, G., Ledent, C. A., Hamon, M., Maldonado, R. J., Lanfumey, L., & Valverde, O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06025.x · Cited by 102
Palacios, J. M., Pazos, Á., & Hoyer, D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4545-5 · Cited by 101
5-HT2 ligands in the treatment of anxiety and depression
Quesseveur, G., Nguyen, H. T., Gardier, A. M., & Guiard, B. P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.719872 · Cited by 98
Fletcher, P. J., Sinyard, J., & Higgins, G. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0453-9 · Cited by 98
Carnell, L., Illi, J., Hong, S. W., & McIntire, S. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3399-05.2005 · Cited by 98
Popova, N. K., Tsybko, A. S., & Naumenko, V. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158814 · Cited by 96
BERG, K., Harvey, J., Spampinato, U., & Clarke, W. P. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00914-x · Cited by 95
Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies
Cremers, T. I. F. H., Rea, K., Bosker, F. J., Wikström, H., Hogg, S., Mørk, A., & Westerink, B. H. C. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301287 · Cited by 91
Self-citationA Serotonin and Melanocortin Circuit Mediates d-Fenfluramine Anorexia
Xu, Y., Jones, J. E., Lauzon, D. A., Anderson, J. G., Balthasar, N., Heisler, L. K., Zinn, A. R., Lowell, B. B., & Elmquist, J. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5412-09.2010 · Cited by 85
Therapeutic Potential of 5-HT2CReceptor Agonists for Addictive Disorders
Higgins, G. A., & Fletcher, P. J. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00025 · Cited by 83
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 84
Research in anxiety disorders: From the bench to the bedside
Garner, M. J., Möhler, H., Stein, D. J., Mueggler, T., & Baldwin, D. S. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.011 · Cited by 83
Implication of 5-HT2B receptors in the serotonin syndrome
Diaz, S. L., & Maroteaux, L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.025 · Cited by 80
Therapeutic Potential of 5-HT2CReceptor Ligands
Hovelsø, N., Cremers, T. I. F. H., & Sotty, F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.180 · Cited by 77
Self-citationEffects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal
Zaniewska, M., McCreary, A. C., Wydra, K., & Filip, M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.006 · Cited by 75
Boothman, L. J., Mitchell, S. N., & Sharp, T. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.020 · Cited by 67
Stukalin, Y., Lan, A., & Einat, H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.034 · Cited by 66
Future Antidepressants: What is in the Pipeline and What is Missing?
Bosker, F. J., Westerink, B. H. C., Cremers, T. I. F. H., Gerrits, M., van der Hart, M. G. C., Kuipers, S. D., van der Pompe, G., Horst, G. J. T., den Boer, J. A., & Korf, J. (2004) · CNS Drugs · doi:10.2165/00023210-200418110-00002 · Cited by 65
Self-citationMongeau, R., Martin, C. B. P., Chevarin, C., Maldonado, R., Hamon, M., Robledo, P., & Lanfumey, L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06932.x · Cited by 51
Olivier, J. D. A., Vinkers, C. H., & Olivier, B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00074 · Cited by 58
Serotonin2Creceptors in the nucleus accumbens are involved in enhanced alcohol‐drinking behavior
Yoshimoto, K., Watanabe, Y., Tanaka, M., & Kimura, M. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08037.x · Cited by 60
Mombereau, C., Kawahara, Y., Gundersen, B. B., Nishikura, K., & Blendy, J. A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.06.009 · Cited by 53
Quérée, P., Peters, S., & Sharp, T. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00406.x · Cited by 56
Nonogaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031600 · Cited by 53
Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?
Hamon, M., & Bourgoin, S. (2006) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(06)70008-6 · Cited by 52
Controversies on the role of 5-HT2C receptors in the mechanisms of action of antidepressant drugs
Martin, C. B. P., Hamon, M., Lanfumey, L., & Mongeau, R. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.001 · Cited by 50
Boas, G. R. V., Lavorato, S. N., Paes, M. M., Galdino, P. M., Rescia, V. C., Cunha, M. S., de Magalhães-Filho, M. F., Ponsoni, L. F., de Carvalho, A. A. V., de Lacerda, R. B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14020148 · Cited by 49
Harvey, B. H., Retief, R., Korff, A., & Wegener, G. (2006) · Metabolic Brain Disease · doi:10.1007/s11011-006-9018-1 · Cited by 48
WOOD, M., & Wren, P. B. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00911-4 · Cited by 46
Zhang, N., Zhang, L., Feng, L., & Yao, L. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.03.013 · Cited by 45
Weikop, P., Yoshitake, T., & Kehr, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.014 · Cited by 45
Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics
Bombardi, C., Grandis, A., Pivac, N., Šagud, M., Lucas, G., Chagraoui, A., Lemaire, V., Deurwaerdère, P. D., & Giovanni, G. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.031 · Cited by 44
Nonogaki, K., Nozue, K., Takahashi, Y., Yamashita, N., Hiraoka, S., Kumano, H., Kuboki, T., & Oka, Y. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007206 · Cited by 43
Bosker, F. J., Tanke, M. A. C., Jongsma, M. E., Cremers, T. I. F. H., Jagtman, E., Pietersen, C. Y., van der Hart, M. G. C., Gladkevich, A. V., Kema, I. P., Westerink, B. H. C., et al. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.001 · Cited by 40
Self-citationKroeze, Y., Peeters, D. G. A., Boulle, F., van den Hove, D., van Bokhoven, H., Zhou, H., & Homberg, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.145 · Cited by 40
Manvich, D. F., Kimmel, H. L., Cooper, D. A., & Howell, L. L. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.195156 · Cited by 38
McDaid, J., Tedford, C. E., Mackie, A. R., Dallimore, J. E., Mickiewicz, A. L., Shen, F., Angle, J. M., & Napier, T. C. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.05.014 · Cited by 38
Murray, F., & Hutson, P. H. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.006 · Cited by 37
Yamada, M., Kawahara, Y., Kaneko, F., Kishikawa, Y., Sotogaku, N., Poppinga, W. J., Folgering, J. H. A., Dremencov, E., Kawahara, H., & Nishi, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.044 · Cited by 37
Xu, Y., Zhang, C., Wang, R., Govindarajan, S. S., Barish, P. A., Vernon, M. M., Fu, C., Acharya, A. P., Chen, L., Boykin, E. R., et al. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.042 · Cited by 36
Grégoire, S., & Neugebauer, V. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-41 · Cited by 36
Ebselen has lithium‐like effects on central 5‐HT2A receptor function
Antoniadou, I., Kouskou, M., Arsiwala, T., Singh, N., Vasudevan, S. R., Fowler, T. G., Cadirci, E., Churchill, G. C., & Sharp, T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14179 · Cited by 35
Santana, N., & Artigas, F. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw148 · Cited by 34
Sotty, F., Folgering, J. H. A., Brennum, L. T., Hogg, S., Mørk, A., Hertel, P., & Cremers, T. I. F. H. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.016 · Cited by 33
Self-citationHuang, M., Dai, J., & Meltzer, H. Y. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.094 · Cited by 30
5-HT2C receptor modulators: a patent survey
Lee, J., Jung, M. E., & Lee, J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.518956 · Cited by 30
de Haes, J. I. U., Cremers, T. I. F. H., Bosker, F. J., Postema, F., Tiemersma‐Wegman, T. D., & den Boer, J. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300721 · Cited by 28
Self-citationKroeze, Y., Peeters, D. G. A., Boulle, F., van den Hove, D., van Bokhoven, H., Zhou, H., & Homberg, J. R. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.60 · Cited by 28
6 5-HT2C Ligands: Recent Progress
Monck, N. J. T., & Kennett, G. A. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00006-9 · Cited by 26
Higgins, G. A., Brown, M., John, J. S., MacMillan, C., Silenieks, L. B., & Thevarkunnel, S. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108064 · Cited by 25
Fathi, D., Abulsoud, A. I., Saad, M. A., Nassar, N. N., Maksimos, M., Rizk, S. M., & Senousy, M. A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119904 · Cited by 25
The Behavioral Genetics of Serotonin: Relevance to Anxiety and Depression
O’Leary, O. F., & Cryan, J. F. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70109-0 · Cited by 25
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 24
Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man
O’Leary, O. F., O'Brien, F. E., O’Connor, R. M., & Cryan, J. F. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.015 · Cited by 22
Serotonin and exercise-induced brain plasticity
(2015) · Neurotransmitter · doi:10.14800/nt.793 · Cited by 22
Esaki, H., Sasaki, Y., Nishitani, N., Kamada, H., Mukai, S., Ohshima, Y., Nakada, S., Ni, X., Deyama, S., & Kaneda, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175653 · Cited by 19
α1-Adrenoceptors modulate citalopram-induced serotonin release
Rea, K., Folgering, J. H. A., Westerink, B. H. C., & Cremers, T. I. F. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.018 · Cited by 18
Self-citationStrain‐dependent serotonin neuron feedback control: role of serotonin2Creceptors
Calcagno, E., & Invernizzi, R. W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06880.x · Cited by 17
Pandey, D., Bhatt, S., Jindal, A., & Gautam, B. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.144935 · Cited by 17
Calcagno, E., Guzzetti, S., Canetta, A., Fracasso, C., Caccia, S., Cervo, L., & Invernizzi, R. W. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009760 · Cited by 17
Metadata
- Authors
- Cremers, T. I. F. H., Giorgetti, M., Bosker, F. J., Hogg, S., Arnt, J., Mørk, A., Honig, G., Bøgesø, K.-P., Westerink, B. H. C., den Boer, H., Wikstrom, H. V., & Tecott, L. H.
- Affiliations
- University of Groningen (NL)
- University of California, San Francisco (US)
- University Medical Center Groningen (NL)
- Lundbeck (Denmark) (DK)
- Corresponding author
- Cremers, Thomas I F H
- Tecott, Laurence H
- ORCID
- Honig, Gerard
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-12
- Volume
- 29
- Issue
- 10
- Pages
- 1782-1789
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2124373758
- Cited by
- 157
- References
- 41
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 10 · 2020: 6 · 2019: 1 · 2018: 6 · 2017: 5 · 2016: 7 · 2015: 9 · 2014: 5 · 2013: 8 · 2012: 5
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- 5-HT2C receptor, serotonin reuptake inhibitors, ketanserin, SB242084, fluoxetine, citalopram, sertraline, depression, antidepressant resistance, tail suspension test, immobility
- MeSH terms
- Animals, Brain Chemistry, Ketanserin, Male, Synaptic Transmission, Serotonin, Serotonin Antagonists, Rats, Wistar, Selective Serotonin Reuptake Inhibitors, Microdialysis, Hindlimb Suspension, Receptor, Serotonin, 5-HT2C, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.